Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The aim is to determine the frequency of RBC transfusion in patients with metastatic "poor
prognosis" germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without
Darbepoetin alfa